Atea Pharmaceuticals, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
AVIR$4.20-4.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · Additional · Accumulated Other · Accumulated · Total | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Paid-in Capital | Comprehensive Gain (Loss) | Deficit | Stockholders' Equity | |
| Balance—January 1, 2025 | 84,463,059 | $84 | $802,770 | $233 | $(364,220) | $438,867 |
| Issuance of common stock upon vesting of restricted stock units, net of employee tax obligations | 1,062,120 | 1 | (486) | — | — | (485) |
| Issuance of common stock under employee stock purchase plan | 54,296 | — | 138 | — | — | 138 |
| Stock-based compensation expense | — | — | 6,951 | — | — | 6,951 |
| Other comprehensive income (loss) | — | — | — | (115) | — | (115) |
| Net loss | — | — | — | — | (34,272) | (34,272) |
| Balance—March 31, 2025 | 85,579,475 | 85 | 809,373 | 118 | (398,492) | 411,084 |
| Issuance of common stock upon vesting of restricted stock units | 177,600 | 1 | (1) | — | — | — |
| Repurchase of common stock | (4,619,597) | (5) | (14,088) | — | — | (14,093) |
| Stock-based compensation expense | — | — | 4,667 | — | — | 4,667 |
| Other comprehensive income (loss) | — | — | — | (81) | — | (81) |
| Net loss | — | — | — | — | (37,161) | (37,161) |
| Balance—June 30, 2025 | 81,137,478 | 81 | 799,951 | 37 | (435,653) | 364,416 |
| Issuance of common stock under employee stock purchase plan | 26,138 | — | 63 | — | — | 63 |
| Issuance of common stock for exercise of stock options | 17,375 | — | 58 | — | — | 58 |
| Repurchase of common stock | (3,054,195) | (3) | (11,423) | — | — | (11,426) |
| Stock-based compensation expense | — | — | 4,517 | — | — | 4,517 |
| Other comprehensive income (loss) | — | — | — | 201 | — | 201 |
| Net loss | — | — | — | — | (42,049) | (42,049) |
| Balance—September 30, 2025 | 78,126,796 | $78 | $793,166 | $238 | $(477,702) | $315,780 |
| Common Stock · Additional · Accumulated Other · Accumulated · Total | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Paid-in Capital | Comprehensive Gain (Loss) | Deficit | Stockholders' Equity | |
| Balance—January 1, 2024 | 83,435,513 | $83 | $750,737 | $207 | $(195,835) | $555,192 |
| Issuance of common stock upon vesting of restricted stock units | 729,032 | 1 | (1) | — | — | — |
| Issuance of common stock under employee stock purchase plan | 58,555 | — | 150 | — | — | 150 |
| Stock-based compensation expense | — | — | 12,586 | — | — | 12,586 |
| Other comprehensive income (loss) | — | — | — | (388) | — | (388) |
| Net loss | — | — | — | — | (63,169) | (63,169) |
| Balance—March 31, 2024 | 84,223,100 | 84 | 763,472 | (181) | (259,004) | 504,371 |
| Issuance of common stock upon vesting of restricted stock units | 198,900 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 12,720 | — | — | 12,720 |
| Other comprehensive income (loss) | — | — | — | (99) | — | (99) |
| Net loss | — | — | — | — | (40,522) | (40,522) |
| Balance—June 30, 2024 | 84,422,000 | 84 | 776,192 | (280) | (299,526) | 476,470 |
| Issuance of common stock upon vesting of restricted stock units | 41,059 | — | 117 | — | — | 117 |
| Stock-based compensation expense | — | — | 12,164 | — | — | 12,164 |
| Other comprehensive income (loss) | — | — | — | 921 | — | 921 |
| Net loss | — | — | — | — | (31,151) | (31,151) |
| Balance—September 30, 2024 | 84,463,059 | $84 | $788,473 | $641 | $(330,677) | $458,521 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.